{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Juvenile dermatomyositis",
      "relation": "indication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_azathioprine",
          "type": "Drug",
          "label": "Azathioprine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_rituximab",
          "type": "Drug",
          "label": "Rituximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_mycophenolate_mofetil",
          "type": "Drug",
          "label": "Mycophenolate mofetil",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclophosphamide",
          "type": "Drug",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_prednisone",
          "type": "Drug",
          "label": "Prednisone",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_hydroxychloroquine",
          "type": "Drug",
          "label": "Hydroxychloroquine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_intravenous_immunoglobulin",
          "type": "Drug",
          "label": "Intravenous immunoglobulin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_belimumab",
          "type": "Drug",
          "label": "Belimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tocilizumab",
          "type": "Drug",
          "label": "Tocilizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "juvenile_dermatomyositis",
          "type": "Disease",
          "label": "Juvenile dermatomyositis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_immunomodulation_pathway",
          "type": "Pathway",
          "label": "Immunomodulation Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_t_cell_activation",
          "type": "Pathway",
          "label": "T Cell Activation",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_methotrexate",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Methotrexate常用于免疫调节"
        },
        {
          "source": "drug_azathioprine",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Azathioprine 作为免疫抑制剂用于相似疾病"
        },
        {
          "source": "drug_rituximab",
          "target": "n_t_cell_activation",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Rituximab用于T细胞相关疾病治疗"
        },
        {
          "source": "drug_mycophenolate_mofetil",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Mycophenolate mofetil的免疫抑制作用"
        },
        {
          "source": "drug_cyclophosphamide",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Cyclophosphamide用于各类自身免疫病"
        },
        {
          "source": "drug_prednisone",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Prednisone广泛用于炎症相关疾病"
        },
        {
          "source": "drug_hydroxychloroquine",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "Hydroxychloroquine用于自身免疫性病"
        },
        {
          "source": "drug_intravenous_immunoglobulin",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "IVIG用于调节免疫反应"
        },
        {
          "source": "drug_etanercept",
          "target": "n_t_cell_activation",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Etanercept用于自身免疫病的治疗"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_t_cell_activation",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Adalimumab用于多种免疫性疾病"
        },
        {
          "source": "drug_belimumab",
          "target": "n_immunomodulation_pathway",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Belimumab用于系统性红斑狼疮"
        },
        {
          "source": "drug_tocilizumab",
          "target": "n_t_cell_activation",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Tocilizumab用于调节免疫反应"
        },
        {
          "source": "n_immunomodulation_pathway",
          "target": "juvenile_dermatomyositis",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "免疫调节路径与皮肌炎关联"
        },
        {
          "source": "n_t_cell_activation",
          "target": "juvenile_dermatomyositis",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "T细胞活化路径与皮肌炎关联"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.78,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Methotrexate acts on the immunomodulation pathway, which is involved in juvenile dermatomyositis."
            ],
            "indication_plausibility": [
              "Commonly used in the treatment of juvenile dermatomyositis."
            ]
          },
          "confidence": "high",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H2",
          "score": 0.76,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Azathioprine acts on the immunomodulation pathway, which is critical in juvenile dermatomyositis."
            ],
            "indication_plausibility": [
              "Utilized effectively in autoimmune conditions, including juvenile dermatomyositis."
            ]
          },
          "confidence": "high",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H3",
          "score": 0.74,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.7,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Rituximab acts on the T cell activation pathway, relevant to juvenile dermatomyositis."
            ],
            "indication_plausibility": [
              "Used in various T-cell mediated diseases, showing promise."
            ]
          },
          "confidence": "high",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H4",
          "score": 0.75,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.7,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Mycophenolate mofetil acts on the immunomodulation pathway."
            ],
            "indication_plausibility": [
              "Proven to be effective in treating autoimmune diseases."
            ]
          },
          "confidence": "high",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H5",
          "score": 0.72,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.3,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Cyclophosphamide influences the immunomodulation pathway."
            ],
            "indication_plausibility": [
              "Used in various autoimmune conditions but with significant safety concerns."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H6",
          "score": 0.7,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.7,
            "safety_risk": 0.3,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Prednisone acts on the immunomodulation pathway."
            ],
            "indication_plausibility": [
              "Widely used for various inflammatory and autoimmune conditions."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H7",
          "score": 0.68,
          "components": {
            "mechanism_fit": 0.65,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.65,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Hydroxychloroquine may influence the immunomodulation pathway."
            ],
            "indication_plausibility": [
              "Used in some autoimmune conditions but less common for dermatomyositis."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H8",
          "score": 0.65,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "IVIG acts on the immunomodulation pathway."
            ],
            "indication_plausibility": [
              "Effective in various immune-mediated disorders."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H9",
          "score": 0.63,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.6,
            "safety_risk": 0.3,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Etanercept acts on the T cell activation pathway."
            ],
            "indication_plausibility": [
              "Used for autoimmune diseases but less evidence in dermatomyositis."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H10",
          "score": 0.62,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.6,
            "safety_risk": 0.3,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab acts on the T cell activation pathway."
            ],
            "indication_plausibility": [
              "Utilized across various autoimmune diseases but less common for dermatomyositis."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H11",
          "score": 0.6,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.3,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Belimumab primarily targets B cell pathways."
            ],
            "indication_plausibility": [
              "Limited evidence in juvenile dermatomyositis specifically."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H12",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.3,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Tocilizumab primarily targets IL-6 and its pathways."
            ],
            "indication_plausibility": [
              "Less support for efficacy in juvenile dermatomyositis."
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "drug_methotrexate",
            "via": [
              "n_immunomodulation_pathway"
            ],
            "to": "juvenile_dermatomyositis",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "Methotrexate的长期安全性",
            "expectation": "如有质疑，增加相应反驳边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "探讨Methotrexate在皮肌炎中的最佳使用时机与疗效",
          "针对免疫调节药物的长期使用安全性进行讨论"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "drug_azathioprine",
            "via": [
              "n_immunomodulation_pathway"
            ],
            "to": "juvenile_dermatomyositis",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "Azathioprine的安全性与效果",
            "expectation": "如有质疑，增加相应反驳边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "Azathioprine疗效机制与临床最佳实践",
          "探讨其在免疫性疾病中的风险收益比"
        ]
      }
    ],
    "pruned_hypotheses": [
      "H3",
      "H4",
      "H5",
      "H6",
      "H7",
      "H8",
      "H9",
      "H10",
      "H11",
      "H12"
    ],
    "seed_request": {
      "should_regenerate": true,
      "reason": "现有候选在机制连通性上不足，重点优先需补充多条不相交路径以提升推理信号。",
      "n": 4
    }
  }
}